arginyl-tryptophyl-n-methylphenylalanyl-tryptophyl-leucyl-methioninamide has been researched along with Anasarca in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Armstrong, RA; Cummings, J; Haslett, C; MacKinnon, AC; Sethi, T; Smyth, JF; Waters, CM | 1 |
1 other study(ies) available for arginyl-tryptophyl-n-methylphenylalanyl-tryptophyl-leucyl-methioninamide and Anasarca
Article | Year |
---|---|
[Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Edema; Enzyme Activation; GTP-Binding Proteins; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neuropeptides; Oligopeptides; Rabbits; Reactive Oxygen Species; Tumor Cells, Cultured | 1999 |